Epcoritamab as Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Dong, Ning ^{[1
]}

Gaballa, Sameh ^{[1
]}

Jain, Michael D. ^{[1
]}

Saeed, Hayder ^{[1
]}

Kareem, Saba ^{[1
]}

Corallo, Salvatore ^{[1
]}

Zhang, Yumeng ^{[1
]}

Shah, Bijal ^{[1
]}

Isenalumhe, Leidy ^{[1
]}

Celeste, Bello ^{[1
]}

Locke, Frederick ^{[1
]}

Sokol, Lubomir ^{[1
]}

Pinilla, Javier ^{[1
]}

Chavez, Julio ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

ABCL; DLBCL; bispecific antibody; epcoritamab; standard of care;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-081

引用

页码：S456 / S456

页数：1

共 50 条

[1] CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL)- a Multicenter Retrospective Study
Dong, Ning
Khadka, Sushmita
Sandoval-Sus, Jose
Rondon, Carlos Silva
Perez, Ariel
Al Sagheer, Tiba
Iqbal, Madiha
Alderuccio, Juan Pablo
Arocho, Cristian Rodriguez
Kareem, Syeda Saba
Jain, Michael D.
Chavez, Julio C.
BLOOD, 2024, 144 : 3091 - 3092
[2] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
Hess, G.
Thieblemont, C.
Clausen, M. R.
Lugtenburg, P.
Balari, Sureda A.
Zinzani, P. L.
Wu, J.
Finn, L.
Vindelov, S. D.
Fox, C. P.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
[3] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Gatwood, Justin
Masaquel, Anthony
Ross, Ryan
Sheinson, Danny
Hossain, Farah
Li, Jia
James, Cameron
Fox, David
BLOOD, 2022, 140 : 7906 - 7907
[4] Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Phillips, Tycel
Thieblemont, Catherine
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Do, Young Rok
Feldman, Tatyana A.
Gasiorowski, Robin
Jurczak, Wojciech
Kim, Tae Min
Lewis, David John
van Der Poel, Marjolein
Poon, Michelle Limei
Kilavuz, Nurgul
Stirner, Mariana Cota
Soong, David
Chiu, Christopher
Chen, Menghui
Sacchi, Mariana
Elliot, Brian
Hutchings, Martin
Lugtenburg, Pieternella
BLOOD, 2022, 140 : 9443 - 9445
[5] Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Karimi, Yasmin H.
Thieblemont, Catherine
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Jurczak, Wojciech
Linton, Kim M.
Hutchings, Martin
Phillips, Tycel
Farooq, Umar
Kim, Won Seog
Dinh, Minh H.
Ghosh, Jagannath
Pallai, Rajash
Wielgos-Bonvallet, Monica
Eskelund, Christian
Lugtenburg, Pieternella J.
Vose, Julie M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S461 - S462
[6] Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
Nastoupil, Loretta J.
Andersen, Clark
Ayers, Amy
Wang, Yucai
Habermann, Thomas M.
Chihara, Dai
Kahl, Brad S.
Link, Brian K.
Ayyappan, Sabarish
Cohen, Jonathon B.
Martin, Peter
Lossos, Izidore S.
Casulo, Carla
Lin, Ruitao
Li, Ziyi
Larson, Melissa A.
Maurer, Matthew J.
Huynh, Lynn
Gao, Chi
Ramasubramanian, Ramya
Duh, Mei Sheng
Mutebi, Alex
Wang, Tongsheng
Jun, Monika
Wang, Anthony
Kamalakar, Rajesh
Kalsekar, Anupama
Cerhan, James R.
Flowers, Christopher R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S442 - S443
[7] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Chaganti, Sridhar
Cwynarski, Kate
Cunningham, David
Locke, Frederick L.
Miklos, David B.
Jacobson, Caron A.
Perales, Miguel-Angel
Kersten, Marie Jose
Oluwole, Olalekan O.
Ghobadi, Armin
Rapoport, Aaron P.
McGuirk, Joseph P.
Pagel, John M.
Munoz, Javier
Farooq, Umar
van Meerten, Tom
Reagan, Patrick M.
Sureda, Anna
Flinn, Ian W.
Vandenberghe, Peter
Song, Kevin W.
Dickinson, Michael
Minnema, Monique C.
Riedell, Peter A.
Leslie, Lori A.
Yang, Yin
Filosto, Simone
Schupp, Marco
To, Christina
Cheng, Paul
Gordon, Leo I.
Radford, John
Westin, Jason R.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
[8] Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
Dreger, P.
Westin, J.
Oluwole, O.
Kersten, M. J.
Miklos, D.
Perales, M. -A
Ghobadi, A.
Rapoport, A.
Sureda, A.
Jacobson, C.
Farooq, U.
van Meerten, T.
Ulrickson, M.
Elsawy, M.
Leslie, L.
Chaganti, S.
Dickinson, M.
Yang, Y.
Schupp, M.
To, C.
Locke, F.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 271 - 272
[9] The First Retrospective Commercial Claims-Based Analysis of CAR T Treated Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Purdum, Anna
Johnson, Jonathan
Bonagura, Anthony
Nyamutswa, Liliosa
Elliott, Caitlin
Lal, Lincy S.
BLOOD, 2020, 136
[10] The efficacy of R-ICE therapy as a salvage treatment for relapse and refractory diffuse large B-Cell lymphoma
Kodaira, Makoto
Yokoyama, Masahiro
Asai, Hiroaki
Yamada, Shuhei
Ueda, Kyoko
Myojo, Tomohiro
Nishimura, Tomoko
Mishima, Yuko
Sakajiri, Sakura
Takeuchi, Kengo
Saotome, Takashi
Terui, Yasuhito
Takahashi, Shunji
Hatake, Kiyohiko
BLOOD, 2007, 110 (11) : 180B - 180B

← 1 2 3 4 5 →